Neutron Capture Therapy for Cancer and Role of PET for the Therapy.
|
Accession number;99A1042719
|
| Title;Neutron Capture Therapy for Cancer and Role of PET for the Therapy. |
| Author;
FUKUDA HIROSHI
(Res. Inst. Tuberculosis and Cancer, Tohoku Univ.)
IMAHORI YOSHIO
(Kyoto Prefect. Univ. of Med.)
HIRATSUKA JUN'ICHI
(Kawasaki Med. Sch.)
ICHIHASHI MASAMITSU
(Kobe Univ., Sch. of Med.)
MISHIMA YUTAKA
(Mishimahifukagakuken)
|
Journal Title;NIRS-M (Natl Inst Radiol Sci)
|
Journal Code:Z0881A
|
ISSN:
|
|
VOL.;NO.132;PAGE.81-90(1999)
|
| Figure&Table&Reference;FIG.10, TBL.2, REF.24 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Boron neutron capture therapy(BNCT) for cancer is a selective radiotherapy using 10B, which releases high LET .ALPHA. particles by the 10B(n, .ALPHA.)7Lireaction. This paper describes BNCT of malignant melanoma using 10B-p-boronophenylalanine(BPA) with special reference to radiobiological basis for treatment dose optimization. From the published data, we decided melanoma control dose and maximum tolerable dose to the skin as 25 and 18 RBE-Gy, respectively. For dose optimization, we measured blood B-10 concentration during neutron irradiation, estimated skin concentration using fixed skin to blood ratio (1.3) and calculated neutron fluence which yield 18 RBE-Gy. A key point of our treatment regimen is that we always irradiate maximum tolerable dose to the normal skin regardless of tumor dose. Because we may not know whether tumor b-10 concentration is high enough or not for tumor control during irradiation. Since 1987, we treated 18 melanoma patients according to this regimen. Local control rate(complete regression) was 60 %, for better than that by conventional radiotherapy. Skin damages are within tolerable limits except for two cases with severe skin damage. Five-year survival evaluated by Kaplan-Meiyer method was 60 % for primary melanomas. 18F-BPA was developed for PET imaging and quantification of B-10 concentration of the tumors. Imahori developed a method for estimating boron concentration in brain tumors based on compartment analysis of 18F-BPA pharmacokinetics. PET imaging using 18F-BPA combined with non-radioactive BPA successfully provided B-10 estimates in brain tumors. Another candidate for neutron capture element is gadolinium(157Gd), which is a contrast media for proton MRI. Yamamoto developed a gadolinium-carborane complex aiming boron and gaadolinium NCT agent. MR imaging of tumor bearing rat was successfully made using 1.5 T unit.... (author abst.) |
|
|
|
Related Articles;
|
|
